Savage Medical Exits Stealth With Over $3 Million to Enable Minimally Invasive Colorectal Tumor Removal
SAN FRANCISCO, Nov. 28, 2023 /PRNewswire/ — Savage Medical, Inc. (“SavageMed”, “Company”, “We”, or “Us”), a San Francisco Bay Area-based, clinical-stage medical technology company enabling minimally invasive colorectal tumor removal, today announced a launch out of stealth with over $3 million in total funding, including oversubscribed financing from leading early-stage medical technology investors including Synergy Ventures, Life Science Angels and AlwaysraiseVC. Capital raised contributes to SavageMed’s ongoing clinical trial of its groundbreaking ColoSeal™ System. SavageMed’s ColoSeal™ has been successfully tested in human clinical trials with positive results.
